-
Sector Analysis
Obesity in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2031
This report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the obesity market through 2031. GlobalData estimates sales of obesity therapeutics to be approximately $10.5 billion across the 7MM in 2021. By 2031, GlobalData expects the obesity market to grow at a strong compound annual growth rate (CAGR) of 32.3%, reaching sales of $173.5 billion by the end of the forecast period. Major drivers of growth in the obesity market during...
-
Sector Analysis
Obesity in 68 Markets - Disease Overview, Product Profiles, Patient Flow, Competitive Assessment and Sales Forecast to 2031
This report covers the 68 geographical markets and provides an Excel-based forecast model for the obesity market through 2031. Across the 68 markets, sales in the obesity market were $12.3 billion in 2021, growing to $206.5 billion in 2031. The seven major markets (US, France, Germany, Italy, Spain, UK, and Japan) represent approximately 85% and 84% of 68-market sales in 2021 and 2031, respectively.
-
Sector Analysis
Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity in 68 Markets - Disease Overview, Product Profiles, Patient Flow, Competitive Assessment and Sales Forecast to 2033
Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity Market Report Overview The GLP-1R agonists in the type 2 diabetes and obesity market size across the 68M was $39.2 billion in 2023. The GLP-1R agonists in the type 2 diabetes and obesity market will witness significant growth during the forecast period. GLP-1R Agonists in the Type 2 Diabetes and Obesity Market Outlook, 2023-2033 ($ Billion) Buy the Full Report to Know More about the GLP-1R Agonists in the...
-
Sector Analysis
Overweight and Obesity Epidemiology Analysis and Forecast to 2031
Overweight and Obesity Epidemiology Analysis Report Overview The combined diagnosed prevalent cases of overweight and obesity were 276,919,516 in the seven major markets (7MM) in 2021. Changes in the total and diagnosed prevalent cases of overweight and obesity throughout the forecast can be attributed to both increasing disease prevalence and the population dynamics in each market. Some heritable traits predispose individuals to obesity, but most factors leading to its onset are behavioral. The widening prevalence of unhealthy diets and sedentary...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.